[1]
Ottman AA, Warner CB, Brown JN. The role of mirtazapine in patients with fibromyalgia: a systematic review. Rheumatology international. 2018 Dec:38(12):2217-2224. doi: 10.1007/s00296-018-4068-3. Epub 2018 Jun 2
[PubMed PMID: 29860538]
Level 1 (high-level) evidence
[2]
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. Mirtazapine versus other antidepressive agents for depression. The Cochrane database of systematic reviews. 2011 Dec 7:(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Epub 2011 Dec 7
[PubMed PMID: 22161405]
Level 1 (high-level) evidence
[3]
de Boer T. The pharmacologic profile of mirtazapine. The Journal of clinical psychiatry. 1996:57 Suppl 4():19-25
[PubMed PMID: 8636062]
[4]
Nutt DJ. Tolerability and safety aspects of mirtazapine. Human psychopharmacology. 2002 Jun:17 Suppl 1():S37-41
[PubMed PMID: 12404669]
[5]
Gandotra K, Chen P, Jaskiw GE, Konicki PE, Strohl KP. Effective Treatment of Insomnia With Mirtazapine Attenuates Concomitant Suicidal Ideation. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2018 May 15:14(5):901-902. doi: 10.5664/jcsm.7142. Epub 2018 May 15
[PubMed PMID: 29734995]
[6]
Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS drug reviews. 2001 Fall:7(3):249-64
[PubMed PMID: 11607047]
[7]
Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU. Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam medical journal. 2018 May:54(2):101-112. doi: 10.4068/cmj.2018.54.2.101. Epub 2018 May 25
[PubMed PMID: 29854675]
[8]
Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, Santos D, Colfax G, Batki SL. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA psychiatry. 2020 Mar 1:77(3):246-255. doi: 10.1001/jamapsychiatry.2019.3655. Epub
[PubMed PMID: 31825466]
Level 1 (high-level) evidence
[9]
Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel, Switzerland). 2020 Jun 4:13(6):. doi: 10.3390/ph13060116. Epub 2020 Jun 4
[PubMed PMID: 32512768]
[10]
Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological reviews. 2018 Apr:70(2):197-245. doi: 10.1124/pr.117.014381. Epub
[PubMed PMID: 29487083]
[11]
Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F. Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2001 Oct:34(10):1303-7
[PubMed PMID: 11593305]
[12]
Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology. 2004 May 25:62(10):1706-11
[PubMed PMID: 15159466]
[13]
Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. International clinical psychopharmacology. 2010 Sep:25(5):302-4
[PubMed PMID: 20715300]
Level 1 (high-level) evidence
[14]
Schneier FR, Campeas R, Carcamo J, Glass A, Lewis-Fernandez R, Neria Y, Sanchez-Lacay A, Vermes D, Wall MM. COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL. Depression and anxiety. 2015 Aug:32(8):570-9. doi: 10.1002/da.22384. Epub 2015 Jun 26
[PubMed PMID: 26115513]
[15]
Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handbook of experimental pharmacology. 2019:250():325-355. doi: 10.1007/164_2018_167. Epub
[PubMed PMID: 30194544]
[16]
Gorman JM. Mirtazapine: clinical overview. The Journal of clinical psychiatry. 1999:60 Suppl 17():9-13; discussion 46-8
[PubMed PMID: 10446735]
Level 3 (low-level) evidence
[17]
Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clinical pharmacokinetics. 2000 Jun:38(6):461-74
[PubMed PMID: 10885584]
[18]
Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ (Clinical research ed.). 2002 Dec 7:325(7376):1332-3
[PubMed PMID: 12468481]
[19]
Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Canadian family physician Medecin de famille canadien. 2010 Mar:56(3):239-41
[PubMed PMID: 20228306]
[20]
Ostenfeld A, Petersen TS, Pedersen LH, Westergaard HB, Løkkegaard ECL, Andersen JT. Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study. Acta psychiatrica Scandinavica. 2022 Jun:145(6):557-567. doi: 10.1111/acps.13431. Epub 2022 Apr 1
[PubMed PMID: 35320582]
[21]
Holzbach R, Jahn H, Pajonk FG, Mähne C. Suicide attempts with mirtazapine overdose without complications. Biological psychiatry. 1998 Nov 1:44(9):925-6
[PubMed PMID: 9807651]
[23]
Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, Salamanca E, Paris N, Daniel C, Gramfort A, Lemaitre G, Bernaux M, Bellamine A, Lemogne C, Airagnes G, Burgun A, Limosin F, AP-HP / Universities / INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Molecular psychiatry. 2021 Sep:26(9):5199-5212. doi: 10.1038/s41380-021-01021-4. Epub 2021 Feb 4
[PubMed PMID: 33536545]
Level 2 (mid-level) evidence
[24]
Stuhec M, Alisky J, Malesic I. Mirtazapine associated with drug-related thrombocytopenia: a case report. Journal of clinical psychopharmacology. 2014 Oct:34(5):662-4. doi: 10.1097/JCP.0000000000000201. Epub
[PubMed PMID: 25118079]
Level 3 (low-level) evidence
[25]
Biswas PN, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. Journal of psychopharmacology (Oxford, England). 2003 Mar:17(1):121-6
[PubMed PMID: 12680749]
[26]
Civalier KA, Krahn LE, Agrwal N. Repeated episodes of neutropenia triggered by mirtazapine. Psychosomatics. 2009 May-Jun:50(3):299-300. doi: 10.1176/appi.psy.50.3.299. Epub
[PubMed PMID: 19567774]
[27]
Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. The effects of mirtazapine on plasma lipid profiles in healthy subjects. The Journal of clinical psychiatry. 2003 Aug:64(8):883-9
[PubMed PMID: 12927002]
[28]
Bowers RD, Valanejad SM, Holombo AA. Mirtazapine-Induced Pancreatitis-A Case Report. Journal of pharmacy practice. 2019 Oct:32(5):586-588. doi: 10.1177/0897190018760645. Epub 2018 Feb 27
[PubMed PMID: 29486665]
Level 3 (low-level) evidence
[30]
DeBellis RJ, Schaefer OP, Liquori M, Volturo GA. Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. Journal of intensive care medicine. 2005 Nov-Dec:20(6):351-3
[PubMed PMID: 16280409]
[31]
Zimmerman M, Chelminski I, Posternak M. A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. The Journal of nervous and mental disease. 2004 Sep:192(9):595-601
[PubMed PMID: 15348975]
[32]
Levis B, Benedetti A, Thombs BD, DEPRESsion Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ (Clinical research ed.). 2019 Apr 9:365():l1476. doi: 10.1136/bmj.l1476. Epub 2019 Apr 9
[PubMed PMID: 30967483]
Level 1 (high-level) evidence
[33]
Salvi J. Calculated Decisions: Columbia-Suicide Severity Rating Scale (C-SSRS). Emergency medicine practice. 2019 May 1:21(5):CD3-4
[PubMed PMID: 31039299]
[34]
Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General hospital psychiatry. 2016 Mar-Apr:39():24-31. doi: 10.1016/j.genhosppsych.2015.11.005. Epub 2015 Nov 18
[PubMed PMID: 26719105]
Level 1 (high-level) evidence
[35]
Retz W, Maier S, Maris F, Rösler M. Non-fatal mirtazapine overdose. International clinical psychopharmacology. 1998 Nov:13(6):277-9
[PubMed PMID: 9861579]
[36]
Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clinical toxicology (Philadelphia, Pa.). 2014 Jan:52(1):20-4. doi: 10.3109/15563650.2013.859264. Epub 2013 Nov 14
[PubMed PMID: 24228948]
[37]
Vignali C, Groppi A, Brandolini F, Avato FM, Talarico A, Gaudio RM, Morini L. Mirtazapine fatal poisoning. Forensic science international. 2017 Jul:276():e8-e12. doi: 10.1016/j.forsciint.2017.04.025. Epub 2017 May 8
[PubMed PMID: 28535979]
[38]
Spiller HA, Griffith JR. The value and evolving role of the U.S. Poison Control Center System. Public health reports (Washington, D.C. : 1974). 2009 May-Jun:124(3):359-63
[PubMed PMID: 19445410]
[39]
Guideline Development Panel for the Treatment of Depressive Disorders. Summary of the clinical practice guideline for the treatment of depression across three age cohorts. The American psychologist. 2022 Sep:77(6):770-780. doi: 10.1037/amp0000904. Epub 2021 Nov 29
[PubMed PMID: 34843274]
Level 1 (high-level) evidence
[40]
Zwarenstein M, Goldman J, Reeves S. Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes. The Cochrane database of systematic reviews. 2009 Jul 8:(3):CD000072. doi: 10.1002/14651858.CD000072.pub2. Epub 2009 Jul 8
[PubMed PMID: 19588316]
Level 1 (high-level) evidence